Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Sep;42(3):121-6.
doi: 10.5152/tud.2016.50318.

A Urologist's Personal View of Prostate Cancer

Paul F Schellhammer  1
Affiliations
Review

A Urologist's Personal View of Prostate Cancer

Paul F Schellhammer. Turk J Urol. 2016 Sep.

Abstract

A urologist's personal experience with multiple surgical, hormonal, and radio/immunotherapeutic options for the treatment of advanced prostate cancer and thoughts on the role of old and new therapies.

Keywords: Cancer; prostate; treatment.

PubMed Disclaimer

References

    1. Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA. 1995;273:289–94. http://dx.doi.org/10.1001/jama.273.4.289. - DOI - PubMed
    1. Vickers AJ, Ulmert D, Sjoberg DD, Bennette CJ, Bjork T, Gerdtsson A, et al. Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40–55 and long term risk of metastasis: case-control study. BMJ. 2013;346:f2023. - PMC - PubMed
    1. Messing EM, Manola J, Yao J, Kiernan M, Crawford D, Wilding G, et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol. 2006;7:472–9. http://dx.doi.org/10.1016/S1470-2045(06)70700-8. - DOI - PubMed
    1. Briganti A, Karnes RJ, Da Pozzo LF, Cozzarini C, Capitanio U, Gallina A, et al. Combination of adjuvant hormonal and radiation therapy significantly prolongs survival of patients with pT2–4 pN+ prostate cancer: results of a matched analysis. Eur Urol. 2011;59:832–40. http://dx.doi.org/10.1016/j.eururo.2011.02.024. - DOI - PubMed
    1. Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol. 2009;181:956–62. http://dx.doi.org/10.1016/j.juro.2008.11.032. - DOI - PMC - PubMed

LinkOut - more resources